ROKIT Healthcare said on the 19th that it officially exported and supplied an "AI cartilage regeneration platform" and a regeneration kit set to Paraguay.
The company said that with this supply, the technology has moved beyond the research and clinical stages and entered commercialization, where actual sales are generated.
Cartilage, once damaged, is difficult to heal naturally, and existing treatments have often been assessed as limited because they frequently form tissue different from normal cartilage. In particular, conventional stem cell therapies have often formed low-durability fibrocartilage, essentially scar tissue.
ROKIT Healthcare's cartilage regeneration platform focuses on addressing these limitations. According to the company, the technology aims to regenerate "hyaline cartilage," which has properties similar to the joint's original cartilage, with a single procedure. Hyaline cartilage is tissue with a structure and strength similar to normal articular cartilage and plays an important role in maintaining joint function.
The company said the technology's regenerative strength was verified in preclinical research conducted at Massachusetts General Hospital (MGH) under Harvard Medical School in the United States, and subsequent clinical trials in Egypt and South America confirmed hyaline cartilage regeneration. A company official said, "This evaluated whether durability comparable to natural cartilage was secured."
ROKIT Healthcare plans to expand its distribution network across South America, starting with this supply to Paraguay. It also plans to gradually build an integrated sales and after-sales service (AS) network spanning North and South America.